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Abstract: Hepatic encephalopathy (HE) is a common complication of liver dysfunction, 
including acute liver failure and liver cirrhosis. HE presents as a spectrum of neuropsychiatric 
symptoms ranging from subtle fluctuating cognitive impairment to coma. It is a significant 
contributor of morbidity in patients with liver disease. HE is observed in acute liver failure, 
liver bypass procedures, for example, shunt surgery and transjugular intrahepatic portosystemic 
shunt, and cirrhosis. These are classified as Type A, B and C HE, respectively. HE can also 
be classified according to whether its presence is overt or covert. The pathogenesis is linked 
with ammonia and glutamine production, and treatment is based on mechanisms to reduce the 
formation and/or removal of these compounds. There is no specific diagnostic test for HE, and 
diagnosis is based on clinical suspicion, excluding other causes and use of clinical tests that may 
support its diagnosis. Many tests are used in trials and experimentally, but have not yet gained 
universal acceptance. This review focuses on the definitions, pathogenesis and treatment of HE. 
Consideration will be given to existing treatment, including avoidance of precipitating factors 
and novel therapies such as prebiotics, probiotics, antibiotics, laxatives, branched-chain amino 
acids, shunt embolization and the importance of considering liver transplant in appropriate cases.
Keywords: hepatic encephalopathy, pathogenesis, treatment, lactulose, rifaximin, probiotics, 
covert hepatic encephalopathy
Introduction
Hepatic encephalopathy (HE) is a hallmark of liver failure and affects up to 40% of 
patients with liver cirrhosis.1 It is defined as a multifactorial neuropsychiatric disor-
der presenting with a broad spectrum of cognitive impairment and neuromuscular 
 dysfunction.1 HE is a significant contributor to repeated hospitalizations for patients 
with liver cirrhosis and severely impacts on the quality of life of both patients and 
caregivers.2 It is a marker of poor prognosis in cirrhotic patients, with reported rates 
of survival of only 36% at 1 year from its first presentation.3
Chronic liver disease is the fifth most common cause of death in the UK, with the 
mortality expected to rise due to increase in cirrhosis caused by alcohol-related liver 
disease, chronic hepatitis C and nonalcoholic fatty liver disease.4,5 Patients commonly 
present to primary and secondary care services with complications such as HE with 
or without a prior diagnosis of chronic liver disease. A milder form of the disorder, 
covert hepatic encephalopathy (CHE) or covert encephalopathy with subtle altera-
tions of cognitive function, also exists.6 Although less severe, patients with CHE are 
at significant risk of interference with their quality of life, including increased falls, 
hospitalizations and progression to overt HE.6–8
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The aims of this review are to provide a comprehensive, 
“state of the art”, account of the pathophysiology, clinical 
manifestations (classification, symptoms, signs and inves-
tigations), current treatments and future targets for the 
management of patients with HE. The review is targeted to 
physicians in primary or secondary care and also to health 
care professionals who are likely to encounter patients with 
liver disease in their professional roles.
Pathogenesis of HE
HE can be classified as three separate clinical entities. Type 
A HE is due to acute liver failure, Type B due to portosys-
temic shunting (e.g., transjugular intrahepatic portosystemic 
shunting procedures) and Type C results as a complication 
of liver cirrhosis.9
Type A HE is associated with an increased intracranial 
pressure that progresses rapidly and may lead to brain her-
niation. The pathophysiology of Type B and C HE is com-
plex and remains under investigation. The main hypothesis 
involves the limited ability of the liver to effectively remove 
nitrogenous waste products, resulting in their accumulation 
and the deleterious effects on the brain due to portosystemic 
shunting.10,11 The key substrates implicated are ammonia 
and glutamine. Several studies have demonstrated that cir-
rhotic patients who had or were experiencing significant 
neuropsychiatric symptoms had elevated blood ammonia 
concentration.12,13 However, the levels were not predictive or 
consistent with the severity of HE.14,15 The exception is in type 
A HE, where Bernal et al have shown that a cut-off level of 
ammonia >200 µmol/L16 is predictive of raised intracranial 
pressure and death.16,17
Glutamine is a key amino acid that plays an important 
signaling role for processes including gene expression, 
cytokine production and cell proliferation. Enhanced 
activity of glutamine is primarily noted in skeletal muscle, 
brain, heart and hepatocytes. Glutamine is metabolized in 
the gut and kidney to ammonia and glutamate. Ammonia 
is then detoxified in the kidneys and liver and excreted as 
urea. In liver failure, ammonia escapes the urea cycle and is 
detoxified to glutamine in various tissues. A vicious cycle is 
formed, whereby increased ammonia concentration due to 
impaired detoxification in the liver further activates gluta-
mine synthesis, leading to increased glutamine catabolism 
resulting in hyperammonemia. The enhanced activity of 
glutamine has been shown to exert adverse effects such 
as swelling of astrocytes in the brain and increases the 
catabolism of branched-chain amino acids (BCAAs) in 
skeletal muscles.18
Manganese has also been implicated in the pathogenesis 
of HE, with elevated plasma levels due to inability of excre-
tion by the liver causing deposition in the basal ganglia.19 This 
has been shown to correlate with pallidal signal hyperinten-
sity observed on magnetic resonance imaging of cirrhotic 
patients.19,20 Furthermore, an animal study by Rivera-Mancia 
et al showed that manganese favored ammonia and glutamine 
accumulation in the brain.21
Additional factors involved in the pathogenesis of HE 
include gut microbiota dysbiosis and small intestinal bacte-
rial overgrowth (SIBO). This pathway has gained interest 
for novel therapies. SIBO in patients with cirrhosis is a 
consequence of reduced gut motility, reduced gastric acid 
secretion, luminal IgA deficiency and malnutrition.22 SIBO 
results in impairment of intestinal barrier integrity, therefore 
increasing bacterial translocation and release of ammonia and 
endotoxins into the circulation.22 Zhang et al24 and Bajaj et 
al,23 in several well-designed studies, have found a distinct 
variation in the population of microbiota between cirrhotics 
and noncirrhotics. Cirrhotics were shown to have an increased 
Bacteriodes/Firmicutes ratio at the expense of commensal 
bacteria.25 Dominant species in cirrhotic patients included 
those of Streptococcaceae, Veillonellaceae, Alcaligenaceae 
and Porphyromonadaceae. These correlated significantly with 
ammonia levels and decreased cognitive function. Also, sev-
eral other bacterial species demonstrated an association with 
increased inflammatory responses in patients with CHE.26 
Tsai et al have recently shown that cirrhotic patients using 
proton-pump inhibitors (PPIs) were more likely to develop 
HE. It is hypothesized that PPIs cause gut dysbiosis leading 
to HE, from the previous findings of the association between 
PPI use and SIBO.27
Sarcopenia (muscle volume depletion) has been shown 
to predict the development of encephalopathy in cirrhotic 
patients.28 Skeletal muscle represents an alternative site of 
ammonia detoxification; therefore, reduced muscle volume 
results in hyperammonemia. The consumption of BCAAs 
in the detoxification of ammonia to glutamine in skeletal 
muscle results in low levels of BCAAs in blood plasma. 
Hanai et al demonstrated that patients with sarcopenia and 
HE due to cirrhosis have low levels of BCAA.28–31 The theory 
is that therapeutic supplementation with BCAAs can, there-
fore, reduce malnutrition and revert the loss of muscle cell 
mass and breakdown of protein driving hyperammonemia.31 
An increase in muscle mass will also help drive increased 
extrahepatic ammonia detoxification. Another main driver of 
sarcopenia is thought to be myostatin, a negative regulator 
of satellite cell differentiation and proliferation. There are 
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higher levels of serum and muscle myostatin in cirrhotic 
patients, and ammonia has been shown to stimulate myostatin 
expression.32
There are additional factors that can precipitate HE 
and act synergistically with ammonia in its pathogenesis 
(Table 1). For example, hyponatremia can exacerbate HE 
due to its osmotic effects on astrocytes,33,34 and patients 
with systemic inflammatory response syndrome are pre-
disposed to HE. In patients with HE, there is an alteration 
in cerebral blood flow35 and enhanced sensitization of the 
brain to inflammatory cytokines by ammonia.36 Moreover, 
there is an increased oxidative stress caused by augmented 
 permeability of the blood–brain barrier contributing to altered 
mental status.37–39
It is becoming increasingly recognized that no single 
entity is responsible for HE, but rather it is a synergistic 
effect of multiple mechanisms (Figure 1).
Diagnosis of HE
Clinical features
HE presents with a wide spectrum of neuropsychiatric 
symptoms which typically begin with subtle psychomotor 
changes.40 This progresses to confusion with the presence of 
asterixis, somnolence and, finally, its most severe form, coma. 
The most common clinical classification used to describe this 
continuum is the West Haven Criteria (Table 2).9
CHE or covert encephalopathy represents the initial stages 
of the disorder that can only be recognized by psychometric 
testing.41 The first feature to emerge is psychomotor slowing 
and difficulties in performing activities of daily living.42,43 
Up to 50% of cirrhotic patients are affected by CHE.42 As 
HE progresses, symptoms become more apparent and can 
be detected clinically. There is alteration in conscious levels 
and disorientation, and disturbance of the sleep–wake cycle 
is often a feature.43 Personality changes may emerge, and 
there can also be motor system abnormalities including 
Figure 1 Contributing factors toward pathophysiology of HE.
Notes: Ammonia is produced from nitrogenous products by bacterial metabolism of urea and proteins in the gut and from deamination of glutamine in the small intestine. 
Normally, ammonia is cleared by liver and kidneys and metabolized in skeletal muscle. However, as a result of liver dysfunction and portosystemic shunting, ammonia cannot 
be cleared adequately. **Increased ammonia levels in the plasma increases metabolism to glutamine (via glutamine synthetase) in astrocytes, which subsequently causes 
intracellular swelling and edema.109
Abbreviation: HE, hepatic encephalopathy.
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Table 1 Precipitating factors to HE
Increased ammonia 
production
Portosystemic 
shunts
Others
Gastrointestinal 
hemorrhage
Spontaneous
Drugs, eg, opioids, 
benzodiazepines
Excess dietary protein 
 
Iatrogenic,  
eg, TIPS 
Infections, eg, 
spontaneous  
bacterial peritonitis
Blood transfusion Malignancy, eg, 
hepatoma
Electrolyte imbalances,  
eg, hypokalemia
Constipation
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hypertonia, hyper-reflexia, dystonia, dyskinesia, upgoing 
plantars and asterixis. Asterixis or “flapping tremor” is a 
negative myoclonus with a loss of postural tone frequently 
seen in the hands, but can affect other parts of the body.44 
The onset of disorientation and asterixis is described as overt 
encephalopathy.
The American and European Associations for the Study 
of the Liver 2014 practice guidelines recommend that HE 
be classified according to four factors:1
1. the underlying etiology as described previously – Type 
A, B or C;
2. severity – using grading system such as West Haven 
Criteria;
3. time course – episodic, recurrent (>1 episode in 6 months) 
or persistent (symptoms always present and can have 
episodes of acute exacerbations); and
4. nonprecipitated or precipitated by factors such as infec-
tions, medications or electrolyte disorders.
Investigations
Diagnosis of HE should be made on a clinical basis after 
exclusion of various conditions that can mimic HE. These 
are outlined in Table 3. Arterial or venous ammonia levels 
can be helpful, but should not be used alone in diagnosis as 
they are often inconsistent, as outlined previously. Electro-
encephalography is valuable to investigate for the presence 
of subclinical seizures. Characteristic triphasic wave changes 
can be seen in HE, alongside subtle signs in CHE.45,46
Imaging modalities such as computed tomography and 
magnetic resonance imaging should be performed to exclude 
differential diagnosis.1,47 In patients with normal neurologic 
examinations, brain imaging is unlikely to be beneficial; also, 
there is probably an overuse of computed tomography scans 
in patients with cirrhosis and altered mental status alone.48 
The main concern in patients with cirrhosis is intracranial 
bleeds due to coagulopathy; yet, this is rare in the absence of 
focal neurologic deficits.49 Other imaging abnormalities on 
magnetic resonance imaging include basal ganglia hyperin-
tensity, and this may be a possible marker for HE and severity 
of liver failure.50–52 In the literature, there is a case describing 
a patient with recurrent HE associated with dynamic changes 
in the basal ganglia hyperintensity pre- and posttreatment.53 
Similar changes have been seen using positron emission 
tomography, but this is currently used as an experimental 
tool to elucidate underlying pathophysiology.54
Diagnosing CHE remains a challenge, and clinicians 
should suspect presence of CHE from inquiring about the 
presence of signs and symptoms. It should be considered in 
patients complaining of difficulties with activities of daily 
living, loss of concentration, lack of ability to function at 
work or with relatives having noted change in cognition.47 
Assessment is done by using validated psychometric tests, 
the gold standard being a combination of the psychometric 
hepatic encephalopathy score,46 but a combination of tests 
may be more accurate.55 A summary of the most established 
tests is highlighted in Table 4.
In an era of technologic advance, development of smart-
phone applications, such as the EncephalApp56 and Stroop 
App,57 are making these tests more accessible and user-
friendly for clinicians and patients.
There are multiple other tools in development for a 
more accurate diagnosis of HE that are not yet validated, 
but are promising. The challenge is to keep the test simple 
Table 3 Differential diagnosis of HE
Metabolic  
encephalopathies
Toxic  
encephalopathies
Intracranial  
events
¨ ¨ ¨
¨ Hypoglycemia ¨ Alcohol ¨ Infection
¨ Hypoxia ¨  Drugs, eg, opioids, 
barbiturates
¨ Encephalitis
¨  Electrolyte  
abnormalities
¨ Heavy metals ¨ Tumors
¨ Uremia ¨ Vascular events
Table 2 West Haven Criteria for hepatic encephalopathy and 
symptoms
WHC Symptoms Clinical f﻿indings
Minimal
Covert 
Psychometric or neuropsychological 
alterations of tests exploring 
psychomotor speed/executive 
functions or neurophysiological 
alterations without clinical evidence 
of mental change 
Nil 
Grade I Trivial lack of awareness
Euphoria or anxiety
Shortened attention span
Impairment of addition or
subtraction
Altered sleep rhythm
Mild asterixis or 
tremor
Grade II 
Overt
Lethargy or apathy
Disorientation for time
Obvious personality change
Inappropriate behavior
Obvious asterixis, 
dyspraxia, slurred 
speech
Grade III Somnolence to semistupor
Responsive to stimuli
Confused
Gross disorientation
Bizarre behavior
Muscular 
rigidity, clonus, 
hyperreflexia
Grade IV Coma Decerebrate 
posturing
Note: Data from a previous study.110
Abbreviation: WHC, West Haven Criteria.
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for patients, but, at the same time, maintain its accuracy in 
diagnosing HE. Examples of these include the animal naming 
test (maximum number of animals listed in 1 minute), one 
study showed that scores obtained in the animal naming test 
directly correlated to grade of encephalopathy.58
Recently, a pilot study from Arasaradnam et al demon-
strated the potential use of exhaled volatile organic com-
pounds to detect HE.59
Management of HE
Patients presenting with overt HE typically will have an 
underlying precipitant such as infection, medications, gas-
trointestinal bleeding or other precipitating factors. The acute 
management relies on detailed history and examination to 
identify and treat these as appropriate. Ninety percent of 
patients can be treated by correcting the precipitating factor.47 
It is important to recognize that a proportion of patients will 
have no underlying precipitant of HE.
Patients with CHE do not usually require treatment unless 
the condition is thought to be adversely affecting their quality 
of life. Current American Association for the Study of Liver 
Diseases (AASLD) guidelines focus on management strate-
gies for overt HE. Patients should be managed empirically 
for HE, while the investigations for precipitating factors or 
mimics of HE are ongoing.47
Prebiotics, probiotics and symbiotics
Lactulose, a prebiotic, is the most widely used nonabsorbable 
disaccharide (NAD) in clinical practice and is recommended 
by AASLD/European Association for the Study of the Liver 
(EASL) guidelines as the first-line treatment for episodes of 
HE. Treatment should continue on resolution of symptoms to 
prevent further episodes. In the colon, lactulose is converted 
to lactic and acetic acid, reducing intraluminal pH and pro-
moting the utilization of ammonia in the metabolism of gut 
bacteria (Figure 2). A 2016 Cochrane meta-analysis of 38 
randomized clinical trials showed that when compared with 
placebo or no intervention, NAD may be associated with 
a beneficial effect on HE. In addition, it showed that NAD 
treatment can reduce serious adverse events associated with 
liver disease, including liver failure, hepatorenal syndrome 
and variceal bleeding.60 The analyses included data for treat-
ment and prevention of HE. Lacitiol is a second-generation 
NAD that has been suggested to have similar effectiveness 
and better tolerance than lactulose,61 although a Cochrane 
review showed that it had no beneficial effects when com-
pared to lactulose. The quality of evidence for lacitiol is poor 
and further research is needed.60
Probiotics are live microorganisms that are believed to 
confer health benefits in a variety of clinical settings.62 In 
HE, probiotics have been shown to act by modulating gut 
microbiota to reduce ammonia levels by several mechanisms, 
including decreased bacterial urease activity, decreased 
ammonia absorption by decreasing the pH and improved 
nutritional status of gut epithelium.63 The most commonly 
used probiotic currently is VSL#3. At present, all evidence 
relating to use of probiotics in the treatment of HE is of poor 
quality, as highlighted by the 2017 Cochrane review of 21 
trials.64 Probiotics had no effect on all-cause mortality, when 
compared to placebo or no treatment. Probiotics may lead 
to improvements in the development of overt HE, quality 
of life and plasma ammonia concentrations, with minimal 
adverse effects. Yet, the review was unable to conclude if 
probiotics were superior to lactulose in the treatment of HE. 
The optimal dose, delivery and species of probiotics to use 
have not been determined.65
Symbiotics are a combination of prebiotics and probiotics 
and their clinical significance in HE remains uncertain. There 
are several randomized controlled trials that demonstrate the 
possible beneficial effects.25,66,67
Table 4 Psychometric tests used in the evaluation of MHE
Test name Description Equipment required
PHES42 Six tests evaluating cognitive and psychomotor processing speed and visuo-motor 
coordination
Pencil and paper
Stroop test57 Tests mental speed and reaction time – written color name differs from the color 
ink it is printed in, and the participant must say the written word not the color
Computer, pencil and paper, or mobile 
phone app
CFF test100 Assessment of ability to detect a light source flickering Specialized equipment
CRT test101 Motor reaction time to auditory stimuli Computer equipment and additional 
hardware
Scan test102 Computerized digit recognition task Computer equipment
ICT103 Test of attention and response inhibition to presented letters Computer equipment
Note: Data from a previous study.94
Abbreviations: CFF, critical flicker frequency; CRT, continuous reaction time; ICT, inhibitory control test; MHE, minimal hepatic encephalopathy; PHES, psychometric 
hepatic encephalopathy score.
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Polyethylene glycol is a purgative laxative agent which 
has been shown in a randomized controlled trial by Rahimi et 
al to be superior to lactulose in improving HE with a quicker 
time for resolution.68 But, more data is required before it can 
be routinely recommended in preference to lactulose.
Nutrition
Nutritional therapy is relevant in HE as a modulator of 
nitrogen metabolism. Historically, dietary protein restric-
tion had been advised to reduce intestinal ammonia 
production. But, this may contribute to sarcopenia and 
actually worsen HE.69 Thus, it was recommended by the 
International Society for Hepatic Encephalopathy and 
Nitrogen Metabolism that 1.2–1.5 g/kg of protein be given 
in small meals distributed throughout the day with a late 
night snack of complex carbohydrates.70 A nasogastric 
feeding tube should be considered if the patient is unable 
to achieve their dietary targets.
If patients are unable to maintain dietary protein intake, 
supplementation with BCAA is an alternative. Oral BCAA 
supplements consist of several essential amino acids thought 
to improve ammonia detoxification. A recent 2015 Cochrane 
review of 16 randomized clinical trials found high-quality 
evidence of clinical benefit, but no effect on mortality, quality 
of life or nutrition parameters.31
Deficiencies of vitamins and electrolytes should also be 
addressed, as they can be associated with a wide range of 
neuropsychiatric symptoms.71 Although not directly impli-
cated in the pathophysiology of HE, they can compound or 
mimic symptoms. The use of additional zinc supplementation 
has been previously studied; a systematic review showed a 
potential improvement in psychometric tests, but its use did 
not affect the recurrence rates of HE.72 More recently, Mousa 
et al conducted a randomized trial which demonstrated that 
antioxidant and zinc supplementation led to a significant 
improvement in baseline neuropsychometric tests in patients 
with CHE, when compared to lactulose therapy.73
Antimicrobials
The use of oral antibiotics to modulate gut flora and reduce 
ammonia production has been researched as a tool to treat 
HE. Neomycin, an aminoglycoside antibiotic which is poorly 
absorbed and reaches high concentrations in the gut, acts as 
a glutaminase inhibitor, thereby reducing ammonia levels.74 
It was the first antibiotic agent to be widely used in HE. 
However, the adverse effects associated with neomycin and 
the development of newer agents preclude its use in current 
clinical practice.
Rifaximin is a semi-synthetic nonabsorbable antibiotic 
derived from rifamycin. When compared with neomycin, 
rifaximin was found to be at least as effective in reducing 
blood ammonia levels, while having less adverse effects such 
as ototoxicity and nephrotoxicity.75–77 It exerts its effects by 
several mechanisms – modulating gut microbiota composi-
Figure 2 Mechanism of action of nonabsorbable disaccharides.
Notes: Lactulose and lacitiol are not absorbed in the small intestine and enter the colon unchanged, where they are metabolized to hydrogen and VFA. Bacteria use these 
as preferred substrate, thereby reducing the production of ammonia and promoting its incorporation into stool for excretion.
Abbreviation: VFA, volatile fatty acids.
Bacteria use VFA as
preferred substrate,
thus reducing
production of
ammonia
Excretion of NH3
secondary to laxative
effect
NH3 NH3
Lactulose fermented
by colonic bacteria to
H2 and VFA
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tion and metabolism and also exhibiting anti-inflammatory 
properties.78 EASL and AASLD guidance recommends the 
use of rifaximin for secondary prophylaxis of overt HE in 
patients who have had further episodes while on lactulose 
therapy. These recommendations are based on evidence 
from a large well-conducted randomized controlled trial.79 
Combination therapy of rifaximin with lactulose has been 
shown to be more effective than the use of rifaximin alone.80
Sidhu et al demonstrated in a randomized open-label trial 
that there was no difference in improvement of cognitive 
function or quality of life in patients with CHE treated with 
rifaximin alone versus lactulose alone.81 An upcoming clini-
cal trial, RiMINI, aims to assess the influence of rifaximin 
versus combination therapy of rifaximin and lactulose on 
the microbiota in patients with CHE.82 Currently, there is no 
evidence for primary or secondary prophylaxis for patients 
with CHE.
Other antimicrobials such as metronidazole and vanco-
mycin have been investigated, but their significant adverse 
effect profile limits their use.83,84
Other therapies
Several other therapies are currently under investigation for 
use as treatment for HE, most of which aim to lower serum 
ammonia levels. l-Ornithine-l-aspartate is used as a supple-
ment that acts by stimulating the urea cycle and glutamine 
synthesis, an important mechanism in the detoxification 
of ammonia.85 Good-quality data from meta-analyses have 
demonstrated that l-ornithine-l-aspartate is more effective in 
improvement of symptoms and reduction in serum ammonia 
levels in cirrhotic patients with CHE and HE, when compared 
to placebo or no intervention control.86
Intravenous albumin infusion is commonly used in patients 
with cirrhosis after reports showed that it improves outcomes 
in cirrhotic patients with spontaneous bacterial peritonitis or 
hepatorenal syndrome. The mechanism of action is thought 
to be improvement in circulatory dysfunction by plasma 
expansion and reduction of oxidative stress.87 Two randomized 
clinical trials have, however, demonstrated that albumin infu-
sion does not have a significant impact on HE in cirrhotics.88,89
A more promising development is the use of ammonia 
scavengers, such as glycerol phenylbutyrate (GPB) and 
ornithine phenylacetate, which lowers ammonia levels by 
providing substrates as an alternative pathway to urea for 
nitrogen metabolism.90 The Phase IIb study (HALT-HE 
[NCT00999167]) on the potential treatment with GPB and 
ornithine phenylacetate is now complete, and results are 
awaited along with the Phase III study (not yet registered 
with clinicaltrials.gov).
See Table 5 for a summary of other potential therapies 
for HE.
Treatment-resistant HE
HE resistant to optimal medical treatment should raise the 
suspicion of large portosystemic shunts, and these can be 
treated by embolization therapy.91 Evidence from stud-
ies suggest that the procedure decreases hospital admis-
sions and improves survival, despite the risks of de novo 
 gastroesophageal varices, worsening ascites and renal dys-
function due to contrast-induced nephropathy.92,93 In Type 
Table 5 Summary of other potential therapies for HE
LOLA* Mechanism of action:
Stimulates enzyme activity leading to increased urea excretion
LOLA is shown in several studies to be as effective as nonabsorbable disaccharides or placebo in improving HE and 
reducing ammonia levels with a few adverse effects86,104
HAS Mechanism of action:
Possible modulation of factors that induce circulatory dysfunction causing oxidative stress
Two small randomized trials suggest that intravenous HAS does not improve resolution of hepatic encephalopathy, but 
may improve survival88,89
Ammonia scavengers  
(e.g., GPB, OP)
Mechanism of action:
Lowers ammonia by providing an alternative pathway to urea for waste nitrogen excretion in the form of phenylacetyl 
glutamine, which is excreted in urine 90
GPB decreases the likelihood of being hospitalized for HE or experiencing an episode of HE.90 Serious adverse effects of 
GPB have been described, which include impaired rate of liver regeneration105 and marked reduction in BCAAs.106 BCAA 
supplementation is recommended alongside GPB.107 OP reduces plasma ammonia levels.108 Current Phase IIb trial (STOP-
HE [NCT01966419]) to investigate the use of OP in acute HE has completed recruitment
Note: *Not available in the USA.
Abbreviations: BCAA, branched-chain amino acid; GPB, glycerol phenylbutyrate; HAS, human albumin solution; HE, hepatic encephalopathy; LOLA, l-ornithine-l-aspartate; 
OP, ornithine phenylacetate.
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B HE caused by iatrogenic shunts created via transjugular 
intrahepatic portosystemic shunt (TIPS) procedure, a reduc-
tion of the stent, that is, reducing caliber of the TIPS, can lead 
to clinical improvement and should be considered in patients 
with severe post-TIPS HE.
Liver transplantation is the only definitive treatment 
option for resistant HE and should be considered in suitable 
candidates presenting with HE. Discussions with transplant 
centers should be initiated early. Strict criteria apply and 
liver transplantation is not without risk, but an assessment 
should be considered in all patients with HE, provided that 
investigations for potential neurodegenerative disorders that 
may worsen posttransplant have been undertaken.47
Unfortunately, there are some patients (e.g., with signifi-
cant comorbidities such as heart failure and disease, renal 
disease and coexisting malignancy) with resistant HE who 
are not suitable candidates for liver transplantation. In these 
patients, the emphasis of care should then be switched to con-
trolling distressing symptoms and providing holistic support 
for the patient and caregivers. Multidisciplinary team input 
is needed, and support should be provided for both patients 
and caregivers.69 Education about preventing constipation 
is paramount, and it may be necessary for administration of 
phosphate enemas in the community. Despite their relative 
contraindication in end-stage liver disease, benzodiazepines 
and opioids may be required, as priorities change to reduce 
distress rather than preserve lucency.94
Future prospects
The management of HE has evolved over the last 10 years 
with the addition on rifaximin into current treatment 
guidelines. There has been an increase in the number of 
randomized controlled trials with good-quality evidence 
describing the use of lactulose, rifaximin, GPB and others. 
More studies are needed to ascertain the pathophysiology 
that will lead to new treatment options of HE. Results of 
several randomized clinical trials, such as HALT-HE and 
STOP-HE, are awaited.
In terms of pathophysiology, there should be an emphasis 
to discover how the different concepts act synergistically to 
lead to development of HE. The research into gut micro-
biota seems promising, and perhaps a look into the role of 
nutritional therapy in modulating gut microbiota would be 
of interest.
There is some evidence for the use of liver support systems 
such as the Molecular Adsorbent Recirculating System and 
Prometheus device. They act by removing circulating toxins 
that accumulate in the blood due to liver dysfunction.95 Both 
devices were well tolerated by patients in liver failure, and their 
effects on HE have been investigated in randomized trials.96 
The MARS study showed that using the MARS system caused 
significant improvement in HE and responded significantly 
faster when compared to standard medical therapy.97 The Relief 
study also showed similar benefits, although survival benefits 
were not demonstrated.98 These devices may have a role in 
patients with incapacitating HE as a bridge to transplantation, 
but may not be appropriate in all causes, given the require-
ment for central venous access and the nonfinite timeline for 
treatment. More studies into the cost-effectiveness are needed, 
together with concerns over the development of sepsis.
Conclusion
HE is a significant contributor to morbidity in patients with 
cirrhosis associated with end-stage liver disease. The unpre-
dictable nature of HE severely impacts on the quality of life 
for patients and relatives. Research into the complexities of 
HE has led to development of new and upcoming treatment 
options. Avoiding the precipitants of HE and combination 
treatment with lactulose and rifaximin remain the mainstay 
of treatment. Future studies should aim to further identify 
novel mechanisms and targets for future treatments with the 
hope of translating this into real benefit for patients with HE.
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